ICAM1 and neoplasm: Although it was established that T cells deficient in ICAM-1 exhibit phenotypes of terminally differentiated cells (28), in our hands in vivo short-term ICAM-1 blockade did not alter the expression of activation markers such as the immune checkpoint inhibitor PD-1 neither produced any difference in the viability of tumor infiltrating leukocytes.